PK5 (PK5) News
Follow PK5 (PK5) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
Allschwil, Switzerland, September 14, 2026Basilea Pharmaceutica Ltd, Allschwil SIX:BSLN, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections
NEWS | Sep 14, 2026, 05:21 AM UTC
L
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba(R) (isavuconazole) in pediatric patients
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba(R) (isavuconazole) in pediatric patients
NEWS | Sep 14, 2026, 05:15 AM UTC